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Background/Aims: A considerable number of patients 
with Crohn’s disease still need intestinal resection surgery. 
Postoperative recurrence is an important issue in Crohn’s 
disease management, including the selection of high-risk 
patients. Eastern Asian patients showed several differences 
from Caucasian patients. Therefore, we investigated the 
postoperative surgical recurrence outcome and identified 
risk factors in Korean patients. Methods: Clinical data of 372 
patients with Crohn’s disease who underwent first intestinal 
resection between January 2004 and August 2014 at 14 
hospitals in Korea were retrospectively reviewed. Results: 
Over the follow-up period, 50 patients (17.1%) showed surgi-
cal recurrence. The cumulative surgical recurrence rate was 
6.5% at 1 year and 15.4% at 7 years. Age under 16 (p=0.011; 
hazard ratio [HR], 5.136; 95% confidence interval [CI], 1.576 
to 16.731), colonic involvement (p=0.023; HR , 2.011; 95% 
CI, 1.102 to 3.670), and the presence of perianal disease at 
surgery (p=0.008; HR, 2.239; 95% CI, 1.236 to 4.059) were 
independent risk factors associated with surgical recurrence. 
Postoperative thiopurine treatment (p=0.002; HR, 0.393; 
95% CI, 0.218 to 0.710) was a protective factor for surgical 
recurrence. Conclusions: Among the disease characteristics 
at surgery, younger age, colonic location, and perianal le-
sions were independent risk factors for surgical recurrence. 
Postoperative thiopurine treatment significantly reduced the 
incidence of surgical recurrence. (Gut Liver 2020;14:331-
337)
Key Words: Crohn disease; Recurrence; Surgery; Risk fac-
tors; Thiopurine 
INTRODUCTION
Crohn’s disease (CD) is a chronic, progressive, and disabling 
inflammatory bowel disease with uncertain etiology and patho-
genesis. CD can affect any part of the gastrointestinal tract with 
systemic manifestations.1 The natural course of the CD is char-
acterized by relapse and remissions. Advancement in medical 
treatment, such as immunomodulators and anti-tumor necrosis 
factor (anti-TNF)-α antibody, has changed the treatment strat-
egy for CD.2 Using anti-TNF-α antibody and immunomodulator 
has achieved mucosal healing that led to long-term mainte-
nance of remission and lowering surgery rate. In a Danish co-
hort study, 5-year cumulative probability of first major surgery 
decreased from 44.7% in a cohort (1979 to 1986) to 19.6% in a 
cohort (2003 to 2011) for CD.3 
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Nevertheless, considerable patients with CD need surgical in-
tervention including a requirement for intestinal resection even 
in the biologic agent treatment era.4 Intestinal resection for CD 
is limited to maintain the complete remission status due to high 
recurrence rate. More than half of the patients experience a 
clinical recurrence within 5 years and surgical recurrence within 
10 years.5 Therefore, the prevention of postoperative recurrence, 
especially the need for repeated intestinal resection after the first 
surgery is a crucial issue.
Selecting high-risk patients for CD recurrence is an important 
problem. Smoking, perforating disease phenotype, and previous 
intestinal resection have been suggested from previous studies 
as factors that predict earlier postoperative recurrence.6,7 A prior 
randomized clinical trial showed that treatment according to 
clinical risk factors of recurrence, early colonoscopy and treat-
ment step-up for recurrence is better for prevention of CD recur-
rence.8 
However, most of the previous studies regarding postopera-
tive recurrence in CD were performed in Western nations and 
mainly Caucasians because of relatively lower incidence CD in 
Eastern Asia. Clinical characteristics such as age at diagnosis, 
cigarette smoking, disease location, behavior, and treatment 
strategy showed differences between the East and the West in 
studies.9,10 Indeed, factors that predict postoperative recurrence 
are still unclear and the data are lacking, especially in Eastern 
Asian countries. Previous studies were limited in terms of small 
patient number, single hospital patients or lack of clinical and 
medication data.11–13 Consequently, research of postoperative 
recurrence is needed to target Eastern Asian patients with CD.
Therefore, we investigated postoperative surgical recurrence 
outcomes and identified the risk factors associated with post-
operative recurrence after intestinal resection surgery in Korean 
patients with CD through a multicenter setting study. 
MATERIALS AND METHODS
1. Patients
Clinical data of 372 patients with CD who underwent first in-
testinal resection due to CD from January 2004 to August 2014 
at 14 hospitals in Korea were retrospectively reviewed. Surgical 
intervention without intestinal resection such as operation lim-
ited in appendectomy, perianal procedure, and strictureplasty 
was not included as intestinal resection surgery. Surgical recur-
rence was defined as additional intestinal resection owing to 
CD, except surgery-related complications.
Patients with the following were excluded: follow-up period 
less than 1 year after intestinal resection (n=43), and patients 
with insufficient clinical, surgical information (n=37). After 
excluding 80 patients based on our exclusion criteria, a total of 
292 patients were finally selected. 
This study was approved by the Institutional Review Board 
of Wonkwang University Hospital in Iksan, Korea (IRB number: 
WKUH 201401-HRE-007).
2. Primary and secondary outcomes
The primary outcome was to investigate the risk factors of 
postoperative surgical recurrences in Korean patients with CD. 
The secondary outcome was to evaluate surgical recurrence 
rates according to risk factors. 
3. Statistical analysis
Data are expressed as the median (interquartile range), num-
ber, or number (%), as appropriate. Factors associated with 
surgical recurrence were investigated using the Kaplan-Meier 
analysis and Cox regression. Any variables identified as sig-
nificant (p<0.05) in the univariate analysis were included in the 
multivariate analysis. 
For comparison of the cumulative probability of surgical re-
currences, Kaplan-Meier estimator survival analysis was used. 
For comparing outcomes, the chi-square test or Fisher exact test 
was used for categorical data, and the Student t-test was used 
for continuous variables. Data analysis was performed using 
SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA). A 
two-sided p-value <0.05 was considered statistically significant.
RESULTS
1. Baseline characteristics
Baseline characteristics of the patients are summarized in 
Table 1. The median age at diagnosis was 25.6 years and at 
surgery was 29.6 years, respectively. Based on Montreal clas-
sification, the majority of the patients presented with ileoco-
lonic location (L3, 46.2%) and non-stricturing, non-penetrating 
behavior (B1, 53.1%) at diagnosis. At the time of surgery, the 
patients’ disease phenotype changed, resulting in the most com-
mon location to terminal ileum (L1, 53.1%) and behavior to 
penetrating type (B3. 66.4%). Most of the patients were diag-
nosed between ages of 17 and 40 (n=196, 67.1%). Patients with 
age under 16 years at diagnosis and at surgery were 63 (21.6%) 
and 34 (11.6%). At diagnosis, 51 patients (17.5%) were current 
smokers and 11 patients (21.6%) stopped smoking before their 
first intestinal resection surgery. Perianal diseases were present-
ed in 135 patients (46.2%) before their first intestinal resection 
surgery.
2. Medical management 
Patients’ medical therapy histories before and after surgery 
is described in Table 2. The median duration from diagnosis to 
surgery was 29.0 months and median follow-up periods after 
intestinal resection was 46.0 months. Thiopurine (azathioprine 
or 6-mercaptopurine) was used in 161 patients (55.1%) before 
surgery and 207 patients (70.9%) after first intestinal resection 
surgery. The number of patients using anti-TNF agents (inflix-
imab or adalimumab) before and after intestinal resection sur-
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gery was 58 (19.9%) and 93 (31.8%). In preoperative anti-TNF 
users, 35 patients (60.3%) reused anti-TNF agents after bowel 
resection. 
3. Postoperative surgical recurrence 
Postoperative surgical recurrence outcome is showed in Table 
3. Fifty patients (17.1%) received second intestinal resection 
surgery due to CD. The cumulative surgical recurrence rate in-
creased from 6.5% at 1 year to 15.4% at 7 years. 
4. Factors associated with surgical recurrence
To determine independent factors associated with surgical re-
currence, variables including baseline characteristics and type of 
medication were analyzed. Among the variables, age at surgery 
(p=0.003), colonic involvement (p=0.009), penetrating phenotype 
(p=0.042), perianal disease (p=0.014), and postoperative thiopurine 
use (p=0.014) were associated with surgical recurrence in univariate 
analysis. In multivariate analysis, age under 16 at surgery (p=0.011; 
hazard ratio [HR], 5.136; 95% confidence intervals [CI], 1.576 to 
16.731), colonic involvement at surgery (p=0.023; HR, 2.011; 95% 
CI, 1.102 to 3.670), and presence of perianal disease before surgery 
(p=0.008; HR, 2.239; 95% CI, 1.236 to 4.059) were independent 
risk factors associated with surgical recurrence. Using postoperative 
thiopurine medication (p=0.002; HR, 0.393; 95% CI, 0.218 to 
0.710) was a protective factor from surgical recurrence (Table 4). 
5. Surgical recurrence outcome according to risk factors 
High-risk group patients and low-risk group patients were 
stratified according to the number of risk factors that showed 
significant in multivariate analysis. Patients who had one risk 
factor were not different from those without risk factors. How-
ever, patients who had two or three risk factors showed higher 
rate of surgical recurrence (Table 5). There was no difference in 
follow-up duration between the two groups. Time to surgical 
recurrence was 84.3 months in patients with the high-risk group 
and 103.4 months in the low-risk group (Table 6). 







   Male 198 (67.8) 198 (67.8)
   Female  94 (32.2)  94 (32.2)
Age, yr 25.6 (17.0–32.0)  29.6 (21.0–35.8)
   A1 (16)  63 (21.6) 34 (11.6)
   A2 (17–40) 196 (67.1) 207 (70.9)
   A3 (>40) 33 (11.3) 51 (17.5)
Location
   L1 (ileal) 116 (39.7) 155 (53.1)
   L2 (colonic) 37 (12.7) 41 (14.0)
   L3 (ileocolonic) 135 (46.2) 92 (31.5)
   L4 (isolated upper disease) 4 (1.4) 4 (1.4)
Behavior
   B1 (non-stricturing, 
      non-penetrating)
130 (44.5) 42 (14.4)
   B2 (stricturing)* 102 (34.9) 86 (29.5)
   B3 (penetrating)† 70 (24.0) 194 (66.4)
   P (perianal disease) 115 (39.4) 135 (46.2)
Current smoking 
   Current smoker 51 (17.5)  40 (13.7)
   Ex-smoker + non-smoker 241 (82.5) 252 (86.3)
CD diagnosed after surgery 49 (16.8) -
Family history of IBD 8 (2.7) -
Data are presented as number (%) or median (range).
CD, Crohn’s disease; IBD, inflammatory bowel disease.
*Stricturing behavior, including the B2 (stricturing) and B2+B3 (stric-
turing and penetrating) phenotypes; †Penetrating behavior, including 
the B3 (penetrating) and B2+B3 (stricturing and penetrating) pheno-
types.
Table 2. Crohn's Disease Medical Therapy (n=292)
Variable Before surgery After surgery
Follow-up duration, mo 29.0 (1.0–74.8) 46.0 (24.0–72.0)
Surgical recurrence - 50 (17.1)
Medication
   5-ASA    225 (77.1) 260 (89.0)
   Corticosteroid  169 (57.9)  99 (33.9)
   Thiopurine  161 (55.1) 207 (70.9)
   Anti-TNF  58 (19.9)  93 (31.8)
      Infliximab  52 (17.8)  78 (26.7)
      Adalimumab  10 (3.4)  21 (7.2)
      Infliximab and adalimumab  4 (1.4)  8 (2.7)
Data are presented as median (range) or number (%).
ASA, aminosalicylic acid; TNF, tumor necrosis factor. 
Table 3. Surgical Recurrence Outcome
Variable
Time after first bowel resection surgery (yr)
1 2 3 4 5 6 7
Surgical recurrence 19/292 (6.5) 23/221 (10.4) 30/175 (17.1) 30/135 (22.2) 21/105 (20.0) 16/74 (21.6) 14/55 (25.5)
Cumulative surgical recurrence 19/292 (6.5) 25/292 (8.5) 34/292 (11.6) 40/292 (13.7) 41/292 (14.0) 43/292 (14.7) 45/292 (15.4)
Data are presented as number/number (%).
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Table 5. Surgical Recurrence Outcome According to Nonmodifiable Risk Factors
No. of risk factors* No. (%) HR  95% CI p-value
0 90 (30.8)
1 113 (38.7) 2.536 0.945–6.803 0.065
2 78 (26.7) 4.110 1.532–11.027 0.005
3 11 (3.8) 12.550 3.818–41.258 0.001
HR, hazard ratio; CI, confidence interval. 
*The risk factors are defined as an age at surgery of less than 16, the presence of perianal disease at surgery, and colonic or ileocolonic location at surgery.
Table 4. Independent Factors Associated with Postoperative Surgical Recurrence
Variables
Univariate Multivariate 
HR 95% CI p-value HR 95% CI p-value
Age at Surgery 0.003 0.011 
   ≤16 5.933 1.8492–19.108 5.136 1.576–16.731
   17-40 2.483 0.876–7.058 2.169 0.759–6.204
   ≥41 Reference Reference
Sex 1.317 0.744–2.334 0.342 
Family history 0.653 0.090–4.740 0.850
Previous appendectomy 1.068 0.500–2.280 0.864 
Diagnosis by initial surgery 1.716 0.723–4.074 0.215
Disease location at surgery 0.009 0.023 
   Ileum Reference Reference
   Colon* 2.173 1.196–3.951 2.011 1.102–3.670
Disease behavior at surgery
   Non-stricturing, non-penetrating 0.381 0.118–1.225 0.092 
   Stricturing† 0.793 0.419–1.501 0.475 
   Penetrating‡ 2.019 1.009–4.041 0.042 0.131 
Perianal disease at surgery 2.017 1.137–3.576 0.014 2.239 1.236–4.059 0.008 
Current smoking at surgery 1.290 0.509–3.268 0.589 
Emergent surgery 0.954 0.501–1.817 0.885 
Preoperative Medication 
   5-ASA 1.015 0.528–1.953 0.964 
   Corticosteroid 0.785 0.450–1.371 0.393 
   Thiopurine 1.191 0.674–2.105 0.546 
   Anti-TNF 0.852 0.399–1.820 0.679
Postoperative Medication
   5-ASA 0.497 0.221–1.116 0.083 
   Corticosteroid 1.092 0.613–1.943 0.765
   Thiopurine 0.496 0.280–0.878 0.014 0.393 0.218–0.710 0.002
   Anti-TNF 0.698 0.378–1.290 0.025
HR, hazard ratio; CI, confidence interval; ASA, aminosalicylic acid; TNF, tumor necrosis factor. 
*Colonic involvement, including L2 (colonic) and L3 (ileocolonic); †Stricturing behavior, including the B2 (stricturing) and B2+B3 (stricturing and 
penetrating) phenotypes; ‡Penetrating behavior, including the B3 (penetrating) and B2+B3 (stricturing and penetrating) phenotypes.
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DISCUSSION
The rapidly increasing tendency with complicated disease 
behavior over the past few decades and postoperative recur-
rence are crucial issues of CD management in Korea.1,11 Eastern 
Asian patients, including Koreans, have shown different clinical 
characteristics and disease courses from Caucasian CD patients.9 
In this study, we identified the clinical characteristics and long-
term outcomes in a large number of Korean patients from mul-
tiple referral centers. 
The differences between our study patients from Western CD 
patients were male predominance (67.8%), a small number of 
patients who were diagnosed CD after age 40 (11.3%), smaller 
proportion of smokers and less frequent colonic involvement at 
surgery, and more common presence of perianal disease before 
surgery.9,14 The reason for these differences is mostly unknown. 
However, it is suggested that altered gut microbiota and genetic 
differences, such as no association with NOD2 and more strong 
association with TNFSF 15 compared with Caucasian, may be 
related.15 Higher exposure to social life or Westernized life style 
in Asian males compared to females might contribute to male 
predominance. Also, age-specific environmental factors or dif-
ferent sensitivities to certain infectious factors might cause a 
second small peak onset of CD.16,17 
Previously, the surgical recurrence rate in Western CD pa-
tients was 20%-50% compared to 14%–25% in Korean CD 
patients including present study within 5 years.5,18 Lower re-
currence rate in Korean patients is might be due to the lower 
smoking rate and the genetic difference making less aggressive 
natural course compared to Western CD patients.13 However, the 
surgical recurrence rate in Western CD patients showed a wide 
range depending on the time period. Moreover, some recent 
studies conducted in the West showed only 8.6% within 8 years 
and 19.1% in 10 years.19,20 Therefore, it is still unclear to consid-
er the ethnic difference as a risk factor for surgical recurrence.
Regarding medical treatment, 55.1% of patients used thio-
purine and only 19.9% of patients used anti-TNF medication 
before their first intestinal resection surgery. These results were 
similar to a recent single-center retrospective study.11 A ten-
dency towards the lower proportion of anti-TNF agents in Asian 
countries compared to the West was well described in several 
studies. Although the efficacy of anti-TNF agents did not differ 
between the West and Asian countries, the lower proportion of 
usage may be originated from limited and strict indications un-
der national insurance coverage in our study period in Korea.9 
In this study, independent risk factors for postoperative surgi-
cal recurrence were younger age, colonic involvement, and the 
presence of perianal lesion at the surgery. Especially, patients 
who had more than 2 risk factors showed higher surgical recur-
rence. Thiopurine medication after surgery reduced surgical 
recurrence significantly. Patients with age under 16 at surgery 
showed much higher surgical recurrence than those with age 
over 16, especially compared to those with age over 40. Recent 
American Gastroenterological Association review also suggested 
younger age at onset as one of the risk factors for postoperative 
recurrence.7 It was indicated that patients with younger age at 
onset have more extensive disease involvement and aggressive 
clinical course characteristics distinct from adult-onset pa-
tients.21–23 Indeed, our study population revealed more frequent 
colonic involvement and penetrating behavior compared to 
adult-onset patients. A different pathogenic mechanism such as 
the presence of a specific mutation in genes encoding the IL10R 
between the age groups may be related.24
There were conflicting results regarding disease location and 
surgical recurrence. In our study, a total of 34 patients (25.6%) 
with colonic involvement showed surgical recurrence with a 
shorter median duration of 111.0 months compared to 119.0 
months in patients with ileal location. It may be originated from 
involved bowel length, but our study was limited due to lack of 
surgical data. Some Western studies suggested that ileal location 
of CD is a predictive factor.25 But other studies showed colonic 
or ileocolonic location is related to higher recurrence rates com-
pared the ileal disease.26,27 Also, in previous studies conducted in 
Korea, the relationship between location and surgical recurrence 
has not been clear.11 
Patients with perianal disease are related to complicated 
disease phenotype, higher risk of surgery, hospitalization, and 
severe disease courses.28 Also, presence of perianal disease is a 
well-known risk factor for postoperative recurrence.6 A recent 
study conducted in Korea demonstrated that patients with peri-
Table 6. Surgical Recurrence Outcome According to Risk Factors
Variable
Low risk group
(0 or 1 risk factor*)
High risk group
(2 or 3 risk factors)
p-value
No. 203 (69.5) 89 (30.5)
Follow-up duration, mo 44.0 (23.0–71.0) 50.0 (26.0–77.5) 0.267
Surgical recurrence 25 (12.3) 25 (28.1) 0.001
Time to surgical recurrence, mo 103.4 (96.7–111.3) 84.3 (73.3–95.3) 0.001
Data are presented as number (%) or median (interquartile range).
*The risk factors are defined as an age at surgery of less than 16, the presence of perianal disease at surgery, and colonic or ileocolonic location at 
surgery.
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anal disease had increased risks of abdominal reoperation (HR, 
1.978; 95% CI, 1.034 to 3.784), and postoperative 5-ASA (HR, 
0.388; 95% CI, 0.175 to 0.858) and thiopurine medication (HR, 
0.499; 95% CI, 0.249 to 0.999) reduced risks of abdominal re-
operation.29 The present study showed similar results in regard 
of perianal disease and benefit of postoperative thiopurine use. 
Also, patients with younger age at onset showed a higher rate 
of perianal disease in both studies. However, unlike the previous 
study, this study showed younger age was one of the risk fac-
tors and postoperative 5-ASA medication was not effective to 
prevent a recurrence.
Many studies from Western countries have shown that smok-
ing is a strong risk factor for the postoperative recurrence of 
CD.4,6,7 Smoking rate in general population in Korea (19.9% to 
25.9%) is comparable or higher than that of Western countries 
(18.4% to 20.7%).30 However, a relatively small number of 
patients were current smokers at the time of diagnosis (n=51, 
17.5%) and surgery (n=40, 13.7%) in the present study. This 
result was consistent with population-based cohort studies in 
Asian patients with CD that showed lower smoking rate (11.8% 
to 28.0%) than Western (57.0%) and Eastern European patients 
(62.0%).31 
Another important finding was that thiopurine medication 
after surgery significantly reduced surgical recurrence. However, 
other medications including anti-TNF agents were not associat-
ed with surgical recurrence in our study. The top-down strategy 
of using an anti-TNF agent early in the postoperative period, as 
well as early in the disease course, has been proposed.2 Recently, 
several studies conducted in Asia showed contrary results from 
the present study.11,32 During our follow-up periods, the use of 
anti-TNF agents, both infliximab and adalimumab, were cov-
ered by national insurance whenever fulfilling following criteria 
of unresponsive effect with more than 2 drugs or moderate CD 
with contraindication to corticosteroid or immunomodulator. 
Therefore, a considerable number of patients could use anti-TNF 
medications after marked endoscopic and clinical recurrence. 
As a result, using anti-TNF medication still could not prevent a 
surgical recurrence. 
There are several limitations in the present study. First, we 
could not evaluate endoscopic recurrence and clinical recur-
rence. Because of the study design which was multicenter and 
retrospective, there was no universal follow-up protocol. There-
fore, we acquired only small number of endoscopic follow-
up results and clinical data such as Crohn’s Disease Activity 
Index, admission or medication step-up due to CD exacerbation. 
Second, we had limited data collection for histological and 
surgical-related factors that may be associated with surgical 
recurrence. Nevertheless, this study has the significance that it is 
the first study involving most of the referral centers nationwide, 
thus reflecting the overall results of Korean patients. 
In conclusion, patients with younger age at onset, colonic 
location, and the presence of perianal disease need careful 
monitoring and intensive management strategies. Thiopurine 
medication in postoperative patients might be effective methods 
for the prevention of surgical recurrence. 
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